Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Genomics, Proteomics, and Target Discovery

Abstract A204: Investigating a novel antitumor molecular target using a chemical proteomic strategy

Hayley R. Evans, Dawen Rong, Roger M. Phillips, Chris W. Sutton and Richard T. Wheelhouse
Hayley R. Evans
1 Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawen Rong
2 School of Pharmacy, University of Bradford, Bradford, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger M. Phillips
1 Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris W. Sutton
1 Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard T. Wheelhouse
2 School of Pharmacy, University of Bradford, Bradford, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-09-A204 Published December 2009
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA

Abstract

Three novel, synthetic biarylheterocycles bearing imidazole terminal groups were discovered with extreme potency (IC50 16–640 nM) against the drug‐resistant (Mitomycin C and EO9) colon carcinoma cell line BE, and also the human ovarian carcinoma A2780 and human non‐small cell lung cancer H460 cell lines. Notably, this biological activity was independent of duplex DNA binding affinity. The compounds were tested in the NCI 60‐cell line panel and COMPARE analysis suggests they are targeting the product of a ‘gene‐like sequence’ of unidentified function.

The identity of the target proteins was explored using an affinity chromatography proteomic strategy. Bespoke affinity matrices were prepared in which test compounds were attached to a solid support through a biotin tag. A synthetic route to compounds containing a biotin moiety in place of one of the imidazole sidechains was developed. Chemosensitivity studies confirmed that the biotinylated compounds retain their activity (IC50 6.25 µM in a susceptible cell line, compared with > 100 µM for an insensitive cell line).

The biotinylated ligands were exposed to protein extracts from the susceptible cell lines and ligand‐protein complexes collected using a streptavidin‐activated affinity column. Bound proteins were eluted from the column and separated using SDS‐PAGE. Proteins were characterised by MALDI MS/MS and identified using database searches.

In parallel, the mechanism of action of the compound series has been investigated using NCI 3D MIND data mining. This suggests the mechanisms of action to be associated with phosphatase‐ and kinase‐mediated cell cycle regulation.

Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A204.

  • Copyright © 2009, American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 8 (12 Supplement)
December 2009
Volume 8, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A204: Investigating a novel antitumor molecular target using a chemical proteomic strategy
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A204: Investigating a novel antitumor molecular target using a chemical proteomic strategy
Hayley R. Evans, Dawen Rong, Roger M. Phillips, Chris W. Sutton and Richard T. Wheelhouse
Mol Cancer Ther December 10 2009 (8) (12 Supplement) A204; DOI: 10.1158/1535-7163.TARG-09-A204

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A204: Investigating a novel antitumor molecular target using a chemical proteomic strategy
Hayley R. Evans, Dawen Rong, Roger M. Phillips, Chris W. Sutton and Richard T. Wheelhouse
Mol Cancer Ther December 10 2009 (8) (12 Supplement) A204; DOI: 10.1158/1535-7163.TARG-09-A204
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Genomics, Proteomics, and Target Discovery

  • Abstract CN03-02: Functional genomics approaches to identify targetable dependencies in cancer cells
  • Abstract PL02-03: The zinc-finger degrome
  • Abstract CN03-01: Functional genomics approaches to the discovery of paralog dependencies in cancer
Show more Genomics, Proteomics, and Target Discovery

Genomics, Proteomics, and Target Discovery: Poster Presentations

  • Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers
  • Abstract A201: Mutation profiling and prognostic value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in colon cancer: Results from NSABP C‐07
  • Abstract A209: Comprehensive analysis of the MET protooncogene promoter regulation
Show more Genomics, Proteomics, and Target Discovery: Poster Presentations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement